Primary Biliary Cholangitis (PBC)
This presentation is most consistent with primary biliary cholangitis (PBC). The combination of pruritus, markedly elevated alkaline phosphatase (279 U/L, approximately 2-3× ULN), mildly elevated ALT (64 U/L), and normal bilirubin (1.1 mg/dL) in a 66-year-old woman creates a classic cholestatic pattern that strongly suggests PBC 1, 2, 3.
Why PBC is the Most Likely Diagnosis
The laboratory pattern is definitively cholestatic, not hepatocellular. When alkaline phosphatase is disproportionately elevated compared to aminotransferases, cholestatic liver disease should be the primary consideration 4. The ACR guidelines explicitly state that "if abnormal ALP levels are seen without impairment of other liver enzymes, the etiology is suspected to be cholestatic in origin" 4.
Key Distinguishing Features:
Pruritus is a hallmark symptom of PBC, occurring in 50-70% of patients and often preceding other manifestations 1, 3. Recent data confirms that pruritus in PBC occurs across all ALP levels and significantly impacts quality of life 5. The British Society of Gastroenterology guidelines note that patients with PSC and PBC commonly present with "pruritus secondary to cholestasis" 1.
The demographic profile fits PBC perfectly. PBC predominantly affects middle-aged to older women (this patient is 66 years old and female), with typical presentation between ages 40-60 3, 6.
The ALP elevation pattern is characteristic. PBC typically shows ALP elevations of 1.5-4× ULN with relatively modest aminotransferase increases 1, 3. This patient's ALP of 279 U/L (roughly 2-3× ULN assuming normal is ~100-120 U/L) with ALT of only 64 U/L creates an R-ratio <2, definitively indicating cholestatic injury 7.
Why Other Diagnoses Are Less Likely
Alcohol-Associated Liver Disease:
The alcohol consumption described (15 oz wine daily, approximately 3 standard drinks) and laboratory pattern argue against this diagnosis. While this represents moderate alcohol use, alcohol-associated liver disease typically presents with:
- AST/ALT ratio >2 (this patient has normal AST of 30 with ALT 64, giving a ratio of ~0.47) 4, 8
- Predominantly hepatocellular pattern, not cholestatic 4
- When alcoholic liver disease does present with markedly elevated ALP (>4× ULN), it's associated with severe alcoholic hepatitis with significant hepatocellular necrosis and cholestasis 9, 10
The 2023 ACR guidelines state unequivocally: "The AST:ALT ratio is generally >2 in alcohol-induced fatty liver disease and <1 in metabolic disease-related fatty liver" 4. This patient's ratio of 0.47 essentially excludes alcohol as the primary etiology.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD):
MASLD presents with a hepatocellular pattern, not cholestatic. Key distinguishing features:
- MASLD shows ALT > AST with AST/ALT ratio <1 4, 8
- ALP is typically normal or only mildly elevated (<2× ULN) 11
- The predominant abnormality is aminotransferase elevation, not ALP 11, 8
While this patient does have ALT > AST, the marked ALP elevation with relatively modest ALT increase creates a cholestatic pattern incompatible with MASLD 4, 11.
Autoimmune Hepatitis (AIH):
AIH presents with predominantly elevated aminotransferases, not ALP. The 2025 EASL guidelines specify:
- AIH is "characterised by predominantly elevated aminotransferase levels" with ALT typically higher than AST 12
- "Less than 20% of patients present with mild elevations in alkaline phosphatase (<2× ULN)" 12
- Significant ALP elevations warrant exclusion of cholestatic variant forms or overlap syndromes 12
This patient's presentation with ALP as the dominant abnormality makes pure AIH unlikely.
Recommended Next Steps
Order anti-mitochondrial antibody (AMA) testing immediately 1, 2, 13, 3. AMA is positive in 90-95% of PBC cases and is highly specific 3, 6. The diagnostic algorithm from the 2019 BSG/UK-PSC guidelines shows that in a patient with elevated ALP and GGT, AMA testing (along with ANA subtypes sp100 and gp210) is the next appropriate step 1.
Obtain abdominal ultrasound to exclude extrahepatic biliary obstruction, though the normal bilirubin makes this less likely 2, 13, 3.
If AMA is positive, the diagnosis of PBC is established and the patient should be referred to hepatology for initiation of ursodeoxycholic acid (UDCA) therapy 3, 6.
If AMA is negative, consider:
- ANA with sp100 and gp210 subtypes (positive in AMA-negative PBC) 1
- MRCP to evaluate for primary sclerosing cholangitis, though the lack of inflammatory bowel disease history makes this less likely 1, 2
- Liver biopsy may be needed if serologic testing is unrevealing 3, 7
Critical Pitfall to Avoid
Do not attribute the cholestatic pattern to alcohol use based solely on the reported consumption. The laboratory pattern is incompatible with typical alcohol-associated liver disease, and the cholestatic presentation with pruritus in a middle-aged woman demands evaluation for PBC 4, 9. Missing PBC delays treatment with UDCA, which can prevent progression to cirrhosis 3, 6.